European Medicines Agency reminds physicians to use Tecentriq (atezolizumab) with nab-paclitaxel, not conventional paclitaxel, when treating breast cancer

An updated review of the Impassion131 study has confirmed that atezolizumab in combination with conventional paclitaxel did not slow down disease progression or reduce deaths in patents with inoperable locally advanced or metastatic triple-negative breast cancer.

Source:

European Medicines Agency